11-keto-boswellic acid profile

ID Source	ID
PubMed CID	9847548
CHEMBL ID	437964
SCHEMBL ID	4388405
MeSH ID	M0415934

Synonym
11-keto-beta-boswellicacid
(3r,4r,4ar,6ar,6bs,8ar,11r,12s,12ar,14ar,14bs)-3-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid
bdbm50241261
11-keto boswellic acid
CHEMBL437964 ,
11-oxo-beta-boswellic acid
3alpha-hydroxy-11-oxours-12-en-24-oic acid
0s3bif6h0q ,
unii-0s3bif6h0q
keto-b-boswellic acid
(3alpha,4beta)-3-hydroxy-11-oxours-12-en-23-oic acid
11-keto-.beta.-boswellic acid (constituent of boswellia serrata) [dsc]
11-keto-.beta.-boswellic acid [dsc]
(3.alpha.,4.beta.)-3-hydroxy-11-oxours-12-en-23-oic acid
(4r)-3alpha-hydroxy-11-oxo-urs-12-en-23-oic acid
LMPR0106180008
SCHEMBL4388405
mfcd06656312
11-keto-beta-boswellic acid, analytical standard
urs-12-en-24-oic acid, 3alpha-hydroxy-11-oxo- (8ci)
3-hydroxy-11-oxo-(3alpha,4beta)-urs-12-en-23-oic acid
11-keto-b-boswellic acid
11-oxo-b-boswellic acid
3a-hydroxy-11-oxo-12-ursen-24-oic acid
AKOS037514519
beta-boswellic acid,11-keto
CS-0018545
11-?keto-?beta-?boswellic acid
HY-N2056
Q27237166
4-trifluoromethylbenzylsulfonylchloride
MS-28710
DTXSID401313244
PD125596
11-keto-beta-boswellic acid (constituent of boswellia serrata)

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Prostaglandin E synthase	Homo sapiens (human)	IC50 (µMol)	6.5000	0.0010	2.0308	10.0000	AID1153839; AID1357408
Prostaglandin G/H synthase 1	Ovis aries (sheep)	IC50 (µMol)	40.0000	0.0003	2.1774	10.0000	AID1617778
Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)	IC50 (µMol)	15.6500	0.0001	1.6847	9.3200	AID1617774; AID376578
Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)	IC50 (µMol)	9.4500	0.7000	4.5804	9.4500	AID409687
Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)	IC50 (µMol)	8.0400	0.0005	3.4984	9.7600	AID409686
Prostaglandin G/H synthase 2	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0001	0.9950	10.0000	AID1617780
Prolyl endopeptidase	Homo sapiens (human)	IC50 (µMol)	36.3200	0.0011	1.9896	9.7500	AID378147
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
prostaglandin biosynthetic process	Prostaglandin E synthase	Homo sapiens (human)
prostaglandin metabolic process	Prostaglandin E synthase	Homo sapiens (human)
signal transduction	Prostaglandin E synthase	Homo sapiens (human)
cell population proliferation	Prostaglandin E synthase	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin E synthase	Homo sapiens (human)
sensory perception of pain	Prostaglandin E synthase	Homo sapiens (human)
regulation of fever generation	Prostaglandin E synthase	Homo sapiens (human)
positive regulation of prostaglandin secretion	Prostaglandin E synthase	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin E synthase	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin E synthase	Homo sapiens (human)
negative regulation of endothelial cell proliferation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte chemotaxis involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
humoral immune response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of bone mineralization	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
dendritic cell migration	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
glucose homeostasis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of fat cell differentiation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of insulin secretion	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of vascular wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response to wounding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cytokine production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cellular response to oxidative stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene A4 biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of response to endoplasmic reticulum stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cell	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxin biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of cell population proliferation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of lipid storage	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
B cell differentiation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
T cell differentiation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
erythrocyte differentiation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
peptidyl-tyrosine dephosphorylation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
insulin receptor recycling	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
glucose homeostasis	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of macrophage differentiation	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
positive regulation of gluconeogenesis	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of inflammatory response	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of T cell receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of chemotaxis	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
regulation of type II interferon-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of positive thymic T cell selection	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STAT	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
positive regulation of JUN kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein dephosphorylation	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of signal transduction	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of signal transduction	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
actin cytoskeleton organization	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of endocytosis	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of intracellular protein transport	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cellular response to unfolded protein	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
peptidyl-tyrosine dephosphorylation	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
IRE1-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor recycling	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of MAP kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of type I interferon-mediated signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STAT	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of protein tyrosine kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein response	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
positive regulation of receptor catabolic process	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to oxidative stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
embryo implantation	Prostaglandin G/H synthase 2	Homo sapiens (human)
learning	Prostaglandin G/H synthase 2	Homo sapiens (human)
memory	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of blood pressure	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell population proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to xenobiotic stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to nematode	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fructose	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to manganese ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cyclooxygenase pathway	Prostaglandin G/H synthase 2	Homo sapiens (human)
bone mineralization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of prostaglandin biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fever generation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic plasticity	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin secretion	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to estradiol	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to lipopolysaccharide	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to vitamin D	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to heat	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to tumor necrosis factor	Prostaglandin G/H synthase 2	Homo sapiens (human)
maintenance of blood-brain barrier	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of protein import into nucleus	Prostaglandin G/H synthase 2	Homo sapiens (human)
hair cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of apoptotic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of cell cycle	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of vasoconstriction	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle contraction	Prostaglandin G/H synthase 2	Homo sapiens (human)
decidualization	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of inflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to glucocorticoid	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of calcium ion transport	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to fatty acid	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to mechanical stimulus	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to lead ion	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to ATP	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to hypoxia	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to non-ionic osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to fluid shear stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of transforming growth factor beta production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of brown fat cell differentiation	Prostaglandin G/H synthase 2	Homo sapiens (human)
positive regulation of platelet-derived growth factor production	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular oxidant detoxification	Prostaglandin G/H synthase 2	Homo sapiens (human)
regulation of neuroinflammatory response	Prostaglandin G/H synthase 2	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	Prostaglandin G/H synthase 2	Homo sapiens (human)
cellular response to homocysteine	Prostaglandin G/H synthase 2	Homo sapiens (human)
response to angiotensin	Prostaglandin G/H synthase 2	Homo sapiens (human)
proteolysis	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
glutathione transferase activity	Prostaglandin E synthase	Homo sapiens (human)
glutathione peroxidase activity	Prostaglandin E synthase	Homo sapiens (human)
prostaglandin-D synthase activity	Prostaglandin E synthase	Homo sapiens (human)
protein binding	Prostaglandin E synthase	Homo sapiens (human)
glutathione binding	Prostaglandin E synthase	Homo sapiens (human)
prostaglandin-E synthase activity	Prostaglandin E synthase	Homo sapiens (human)
arachidonate 5-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
hydrolase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
integrin binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
protein binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
protein kinase binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
syntaxin binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
receptor tyrosine kinase binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
STAT family protein binding	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
RNA binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
insulin receptor binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
zinc ion binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
enzyme binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein kinase binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
receptor tyrosine kinase binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cadherin binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein phosphatase 2A binding	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activity	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
peroxidase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
prostaglandin-endoperoxide synthase activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
enzyme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
heme binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein homodimerization activity	Prostaglandin G/H synthase 2	Homo sapiens (human)
metal ion binding	Prostaglandin G/H synthase 2	Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	Prostaglandin G/H synthase 2	Homo sapiens (human)
serine-type endopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
protein binding	Prolyl endopeptidase	Homo sapiens (human)
serine-type peptidase activity	Prolyl endopeptidase	Homo sapiens (human)
oligopeptidase activity	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nuclear envelope lumen	Prostaglandin E synthase	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin E synthase	Homo sapiens (human)
membrane	Prostaglandin E synthase	Homo sapiens (human)
perinuclear region of cytoplasm	Prostaglandin E synthase	Homo sapiens (human)
membrane	Prostaglandin E synthase	Homo sapiens (human)
extracellular region	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular space	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nucleoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear matrix	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear membrane	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
secretory granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
perinuclear region of cytoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
ficolin-1-rich granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
plasma membrane	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
nucleoplasm	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
endoplasmic reticulum	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
cytosol	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
endosome lumen	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
cytoplasm	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
nucleus	Tyrosine-protein phosphatase non-receptor type 2	Homo sapiens (human)
plasma membrane	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasm	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
mitochondrial matrix	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
early endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytosol	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
mitochondrial crista	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endosome lumen	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
sorting endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membrane	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
protein-containing complex	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
endoplasmic reticulum	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
cytoplasm	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
early endosome	Tyrosine-protein phosphatase non-receptor type 1	Homo sapiens (human)
nuclear inner membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
nuclear outer membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum lumen	Prostaglandin G/H synthase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Prostaglandin G/H synthase 2	Homo sapiens (human)
caveola	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
protein-containing complex	Prostaglandin G/H synthase 2	Homo sapiens (human)
neuron projection	Prostaglandin G/H synthase 2	Homo sapiens (human)
cytoplasm	Prostaglandin G/H synthase 2	Homo sapiens (human)
nucleus	Prolyl endopeptidase	Homo sapiens (human)
cytoplasm	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
membrane	Prolyl endopeptidase	Homo sapiens (human)
cytosol	Prolyl endopeptidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (94)

Assay ID	Title	Year	Journal	Article
AID691822	Solubility of the compound in modified fasted state simulated intestinal fluid at 5 mg/mL after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID458320	Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion at 20 uM by scintillation counting	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
AID691810	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and pluronic f68 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1204860	Inhibition of IL-1 beta-induced COX-2 activity in human SW982 cells assessed as enzyme activity at LD50 treated for 24 hrs prior to incubation with IL-1 beta for 6 hrs (Rvb = 100.0%)	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID458321	Inhibition of human recombinant 11beta-HSD2 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion at 20 uM by scintillation counting	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational approaches.
AID590124	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid.
AID1272078	Cytotoxicity against human FR2 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID1617776	Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol orange as	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID691798	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis in presence of 3:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID590119	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid.
AID691801	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis in presence of 3:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID638415	Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID1204857	In vivo inhibition of COX-2 activity in Complete Freund's adjuvant-induced arthritic albino Wistar rat serum assessed as decrease in peroxidase activity measured as TMPD oxidation rate at 10 mg/kg administered via gavage daily started from day 7 and conti	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID691828	Plasma concentration in rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation relative to non-formulated compound after 2 hrs	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID378147	Inhibition of prolyl endopeptidase	2005	Journal of natural products, Feb, Volume: 68, Issue:2	Bioactive constituents from Boswellia papyrifera.
AID691786	Solubility of the compound in water at 5 mg/mL after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691796	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis in presence of 10:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691815	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound to Lipoid S100 ratio 1:3 in presence of 5:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1204861	Inhibition of IL-1 beta-induced LOX activity in human SW982 cells assessed as enzyme activity at LD50 treated for 24 hrs prior to incubation with IL-1 beta for 6 hrs (Rvb = 100.0%)	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID691790	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1197685	Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Synthesis and antitumor activity of ring A modified 11-keto-β-boswellic acid derivatives.
AID303270	Cytotoxicity against human DU145 cells at 10 uM after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID1272076	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression at 10 uM after 5 hrs	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID691814	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and vitamin E-TPGS ratio 1:2:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1197687	Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Synthesis and antitumor activity of ring A modified 11-keto-β-boswellic acid derivatives.
AID691806	Permeability from apical to basolateral side of human Caco2 cells at compound to Lipoid S100 ratio 1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691803	Permeability from apical to basolateral side of human Caco2 cells at compound to Lipoid S100 ratio 1:3	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691823	Solubility of the compound in HBSS buffer containing 4% bovine serum albumin at 5 mg/mL after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1204855	Antiinflammatory activity against carrageenan-induced albino Wistar rat hind paw edema model assessed as decrease in paw volume at 10 mg/kg, ip treated 45 mins prior to carrageenan injection measured at the end of 24 hrs after carrageenan injection by ple	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID1153839	Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1.
AID303269	Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID1617774	Inhibition of human recombinant 5-LOX expressed in insect cells assessed as decrease in production of 5-HPETE and 5-HETE using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric io	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID691824	Solubility of the compound in fasted state simulated intestinal fluid at compound, Lipoid S100 and pluronic f127 ratio 1:1:1 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691804	Permeability from apical to basolateral side of human Caco2 cells at compound to Lipoid S100 ratio 1:3 in presence of 5:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1617777	Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID307623	Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg relative to control	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID691794	Solubility of the compound in fed state simulated intestinal fluid at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691811	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and pluronic f127 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691820	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and pluronic f68 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691807	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and tween 80 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691788	Solubility of the compound in fed state simulated intestinal fluid at 5 mg/mL after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID638416	Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID691785	Drug level in rat brain at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691792	Solubility of the compound in water at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID638414	Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID691829	Plasma concentration in rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation relative to non-formulated compound after 8 hrs	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID638413	Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID1617775	Inhibition of human recombinant 5-LOX expressed in insect cells assessed residual activity using arachidonic acid at 42 uM as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol o	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID691808	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and vitamin E-TPGS ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID307624	Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model at 250 mg/kg relative to control	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats.
AID1204859	Cytotoxicity against human SW982 cells after 24 hrs by MTT assay	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID1617780	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID638417	Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID1617779	Inhibition of ovine recombinant COX1 assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1204858	Reduction in neutrophil infiltration in Complete Freund's adjuvant-induced arthritic albino Wistar rat ankle joint at 10 mg/kg administered via gavage daily started from day 7 and continued till day 21 after CFA injection by hematoxylin-eosin staining bas	2015	European journal of medicinal chemistry, Jun-15, Volume: 98	Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents.
AID638412	Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID691818	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and vitamin E-TPGS ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691787	Solubility of the compound in fasted state simulated intestinal fluid at 5 mg/mL after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691817	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at 5 mg/mL	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1197686	Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Synthesis and antitumor activity of ring A modified 11-keto-β-boswellic acid derivatives.
AID303273	Cytotoxicity against human HT29 cells at 10 uM after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID1197684	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Synthesis and antitumor activity of ring A modified 11-keto-β-boswellic acid derivatives.
AID691799	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis in presence of 10:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691789	Solubility of the compound in water at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID376578	Inhibition of lipoxygenase 5 product formation from endogenous substrate in Calcium and ionophore-stimulated polymorphonuclear leukocyte	2000	Journal of natural products, Aug, Volume: 63, Issue:8	Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues.
AID691821	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and pluronic f127 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691784	Drug level in rat brain at 240 mg/kg, po	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1272079	Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced TNFalpha expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID1272077	Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 expression at 10 uM after 5 hrs	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID1617781	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis r	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID409687	Inhibition of TCPTP by pNPP assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
AID691797	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis in presence of 5:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1868239	Inhibition of recombinant human SENP1 assessed as reduction in deSUMOylation of RanGAP1-SUMO1 at 5 uM using RanGAP1-SUMO1 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins relative to control	2022	Journal of natural products, 05-27, Volume: 85, Issue:5	Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study.
AID691819	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and gelucire 44/14 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691813	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound to Lipoid S100 ratio 1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691816	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound to Lipoid S100 ratio 1:3	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691793	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID409686	Inhibition of PTP1B by pNPP assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.
AID691812	Permeability from apical to basolateral side of human Caco2 cells assessed as mass balance at compound, Lipoid S100 and tween 80 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691805	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and vitamin E-TPGS ratio 1:2:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1272080	Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced IL-6 expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA	2016	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2	Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID691825	Apparent permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and pluronic f127 ratio 1:1:1 using modified fasted state simulated intestinal fluid	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691827	Apparent permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and pluronic f127 ratio 1:1:1 using HBSS buffer	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691809	Permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and gelucire 44/14 ratio 1:1:1	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691795	Solubility of the compound in water at pH 6.5	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691826	Apparent permeability from apical to basolateral side of human Caco2 cells at compound, Lipoid S100 and pluronic f127 ratio 1:1:1 using modified fed state simulated intestinal fluid	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID691802	Permeability from apical to basolateral side of human Caco2 cells at 5 mg/mL	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID303272	Cytotoxicity against human 502713 cells at 10 uM after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID1197688	Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Synthesis and antitumor activity of ring A modified 11-keto-β-boswellic acid derivatives.
AID1617778	Inhibition of ovine recombinant COX1 assessed as decrease in formation of PGE2 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID303271	Cytotoxicity against human SW620 cells at 10 uM after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23	Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID691791	Solubility of the compound in fed state simulated intestinal fluid at compound to Lipoid S100 ratio 1:1 after 3 hrs by HPLC analysis	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
AID1357408	Inhibition of mPGES1 in human A549 cell microsomal membrane using pGH2 as substrate pretreated for 15 mins followed by substrate addition and measured after 1 min by RP-HPLC method	2018	European journal of medicinal chemistry, Jun-10, Volume: 153	Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.
AID691800	Solubility of the compound in fasted state simulated intestinal fluid at compound to Lipoid S100 ratio 1:3 after 3 hrs by HPLC analysis in presence of 5:1 molar ratio of Lipoid S100 to tween 80	2012	Journal of natural products, Oct-26, Volume: 75, Issue:10	Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (31.25)	29.6817
2010's	10 (62.50)	24.3611
2020's	1 (6.25)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (12.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
berberine [no description available]	3.27	1	alkaloid antibiotic; berberine alkaloid; botanical anti-fungal agent; organic heteropentacyclic compound	antilipemic drug; antineoplastic agent; antioxidant; EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor; EC 1.21.3.3 (reticuline oxidase) inhibitor; EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.11.10 (IkappaB kinase) inhibitor; EC 3.1.1.4 (phospholipase A2) inhibitor; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor; EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; geroprotector; hypoglycemic agent; metabolite; potassium channel blocker
celecoxib [no description available]	2.1	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
embelin embelin: from Embelia fruit (Myrsinaceae). embelin : A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.	3.27	1	dihydroxy-1,4-benzoquinones	antimicrobial agent; antineoplastic agent; hepatitis C protease inhibitor; plant metabolite
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.46	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	2.11	1	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.1	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.21	1	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
propyl gallate Propyl Gallate: Antioxidant for foods, fats, oils, ethers, emulsions, waxes, and transformer oils.	2.02	1	trihydroxybenzoic acid
rolipram [no description available]	2.13	1	pyrrolidin-2-ones	antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
streptonigrin [no description available]	3.51	1	pyridines; quinolone	antimicrobial agent; antineoplastic agent
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.46	2	mitomycin	alkylating agent; antineoplastic agent
cysteine [no description available]	2.02	1	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	2.02	1	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
glycyrrhetinic acid [no description available]	2.49	2	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
oleanolic acid [no description available]	2.49	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.75	3	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
butylated hydroxyanisole [no description available]	2.02	1
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.03	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
dexibuprofen dexibuprofen: structure in first source	2.03	1	ibuprofen	non-narcotic analgesic; non-steroidal anti-inflammatory drug
zileuton [no description available]	2.21	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
ursolic acid [no description available]	4.12	4	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
medicagenic acid medicagenic acid: aglycone constituent of lucerne saponins, upon which their fungastatic & hemolytic activity depends	2.21	1	triterpenoid
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.27	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
salvin salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)	3.27	1	abietane diterpenoid; carbotricyclic compound; catechols; monocarboxylic acid	angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; antioxidant; apoptosis inducer; food preservative; HIV protease inhibitor; plant metabolite
atranorin atranorin: RN given refers to parent cpd; structure given in first source	3.27	1	carbonyl compound
beta-amyrin beta-amyrin: alpha-amyrin is also available; a 5 ring triterpene derived from oleanane that differs from alpha-amyrin in having the 29-carbon at the 20 position; RN given refers to (3 beta)-isomer. beta-amyrin : A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.	2.21	1	pentacyclic triterpenoid; secondary alcohol	Aspergillus metabolite; plant metabolite
alpha-amyrin alpha-amyrin: beta-amyrin is also available; a 5 ring triterpene derived from taraxasterol that differs from beta-amyrin in having the 29-carbon at the 19 position. alpha-amyrin : A pentacyclic triterpenoid that is ursane which contains a double bond between positions 12 and 13 and in which the hydrogen at the 3beta position is substituted by a hydroxy group.	2.21	1	pentacyclic triterpenoid; secondary alcohol
Tormentic acid tormentic acid: aglycone of Rosamultin	3.63	2	triterpenoid	metabolite
hederagenin [no description available]	2.21	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid; sapogenin	plant metabolite
echinocystic acid [no description available]	3.51	1	triterpenoid
madecassic acid [no description available]	2.04	1	monocarboxylic acid; pentacyclic triterpenoid; tetrol	antioxidant; plant metabolite
arjunolic acid arjunolic acid: oleanane type; isol from Cochlospermum tinctorium (Bixaceae); structure given in first source; RN given refers to (2alpha,3beta,4alpha)-isomer; RN for cpd without isomeric designation not avail 12/89. arjunolic acid : A pentacyclic triterpenoid that is olean-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). Isolated from Symplocos lancifolia and Juglans sinensis, it exhibits antioxidant and antimicrobial activities.	2.21	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid	antibacterial agent; antifungal agent; antioxidant; metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	2.21	1	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
uvaol uvaol: from Vauquelinia corymbosa (Rosaceae)	3.94	3	triterpenoid	metabolite
gypsogenin gypsogenin: originally from Gypsophila species; structure in first source. gypsogenin : A sapogenin that is olean-12-en-28-oic acid substituted by a beta-hydroxy group at position 3 and an oxo group at position 23.	2.21	1	aldehyde; monocarboxylic acid; pentacyclic triterpenoid; sapogenin
erythrodiol [no description available]	2.49	2	diol; pentacyclic triterpenoid; primary alcohol; secondary alcohol	plant metabolite
asiatic acid [no description available]	3.93	3	monocarboxylic acid; pentacyclic triterpenoid; triol	angiogenesis modulating agent; metabolite
boswellic acid boswellic acid: ursane type; RN given refers to (3alpha,4beta)-isomer; active principle of salai guggal; see also record for salai guggal	10.64	13	triterpenoid
perlatolinic acid perlatolinic acid: C25-H32-O7; structure in first source	3.27	1	carbonyl compound
scoparianoside b scoparianoside B: isolated from the fruit of Japanese Kochia scoparia; structure given in first source	3.51	1	triterpenoid saponin
sitosterol, (3beta)-isomer Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3.	2.05	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol	anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor
pomolic acid pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source	3.51	1	triterpenoid	metabolite
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	2.03	1	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
hyperforin hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.	3.27	1
carnosol carnosol: isolated from Lepechinia hastata	3.27	1	diterpenoid
ganoderic acid a [no description available]	2.05	1	triterpenoid
euscaphic acid euscaphic acid: isolated from medicinal plant, Euscaphis japonica Pax.; structure; RN given refers to 2alpha,3alpha-isomer. euscaphic acid : A pentacyclic triterpenoid that is urs-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 19 respectively (the 2alpha,3alpha-stereoisomer). It has been isolated from the leaves of Rosa laevigata.	3.51	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid; triol	plant metabolite
olivetoric acid olivetoric acid: isolated from Pseudevernia furfuracea; structure in first source	3.27	1	carbonyl compound
methyl ursolate methyl ursolate: structure in first source	2.05	1
boswellic acid [no description available]	2.77	3
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	3.27	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	3.63	2	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
sc 560 SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.	2.21	1	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
kaempferol [no description available]	3.27	1	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
3-methylquercetin isorhamnetin : A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.	3.27	1	7-hydroxyflavonol; monomethoxyflavone; tetrahydroxyflavone	anticoagulant; EC 1.14.18.1 (tyrosinase) inhibitor; metabolite
guttiferone e guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source	3.27	1
corosolic acid [no description available]	4.12	4	triterpenoid	metabolite
acetyl-11-ketoboswellic acid acetyl-11-ketoboswellic acid: a 5-lipoxygenase inhibitor; structure given in first source	5.04	12	triterpenoid
3-o-acetyl-beta-boswellic acid 3-O-acetyl-beta-boswellic acid: isolated from Boswellia serrata; structure in first source	4.69	8
3-epioleanolic acid [no description available]	2.04	1	triterpenoid	metabolite
11-deoxy glycyrrhetinic acid [no description available]	2.21	1	triterpenoid
alpha-amyrenone alpha-amyrenone: from Marsdenia officinalis Tsiang	2.21	1
oleanonic acid oleanonic acid: structure in first source	2.04	1
roburic acid roburic acid : A tetracyclic triterpenoid with formula C30H40O2 that is isolated from the roots of Gentiana dahurica and Gentiana macrophylla.	3.68	2	monocarboxylic acid; olefinic compound; tetracyclic triterpenoid	plant metabolite
beta-Elemonic acid beta-elemonic acid: extracted from Boswellia carterii	2.46	2	triterpenoid
arzanol arzanol: a prenylated alpha-pyrone-phloroglucinol etherodimer from Helichrysum italicum subsp.microphyllum; has antioxidant and cytotoxic activity; structure in first source	3.27	1
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	2.02	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger

Condition	Relationship Strength	Studies
Polyarthritis [description not available]	2.47	2
Anasarca [description not available]	2.03	1
Arthritis Acute or chronic inflammation of JOINTS.	2.47	2
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.03	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.04	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.04	1
Innate Inflammatory Response [description not available]	3.09	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.09	1
Epithelial Ovarian Cancer [description not available]	3.33	1
Cancer of Ovary [description not available]	3.33	1
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	3.33	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	3.33	1

11-keto-boswellic acid

Cross-References

Synonyms (35)

Protein Targets (7)

Inhibition Measurements

Biological Processes (146)

Molecular Functions (34)

Ceullar Components (30)

Bioassays (94)

Research

Studies (16)

Study Types

11-keto-boswellic acid

Cross-References

Synonyms (35)

Protein Targets (7)

Inhibition Measurements

Biological Processes (146)

Molecular Functions (34)

Ceullar Components (30)

Bioassays (94)

Research

Studies (16)

Study Types

Related Drugs (67)

Related Conditions (12)